Aims
Our studies have shown that the association between integrin-associated protein (IAP) and SHPS-1 regulates the response of cells including osteoclasts, osteoblasts, smooth muscle and retinal endothelial cells to Insulin-like growth factor-I (IGF-I). The aims of this study were to determine whether the regulation of IGF-I responsiveness by IAP/SHPS-1 association is a generalized response of endothelial cells, to identify the mechanism by which IAP/SHPS-1 association contributes to changes in endothelial cell responses to IGF-I and to determine whether inhibiting their association alters pathophysiologic changes that occur in vivo.
Methods and Results
Endothelial cells, maintained in 5mmol/l glucose, showed constitutive cleavage of the extracellular domain of IAP (containing the SHPS-1 binding site) and IAP/SHPS-1 association was not detected. In contrast, hyperglycemia inhibited IAP cleavage allowing IAP/SHPS-1 association and IGF-I stimulated SHPS-1 tyrosine phosphorylation. Exposure to an anti-IAP antibody that disrupts IAP/SHPS-1 association inhibited IGF-I stimulated tube formation and increased permeability. Rodent models of endothelial cell dysfunction were used to investigate the role of IAP-SHPS-1 association in endothelial cell function in vivo. Basal IAP/SHPS-1 association was not detected in retinal extracts in normal rats but was fully restored in rats with diabetes. The anti-IAP antibody inhibited IAP/SHPS-1 association and reduced retinal vascular permeability and leukocyte adherence to levels that were similar to non-diabetic rats. The antibody also significantly inhibited aberrant neovascularization that was induced by hypoxia.
Conclusions
Our results demonstrate that the increase in IAP/SHPS-1 association contributes to the pathophysiologic changes in the endothelium that are induced by hyperglycemia and hypoxia.